Molecular biomarkers and ablative therapies for Barrett's esophagus.

about

Changes in gene expression of neo-squamous mucosa after endoscopic treatment for dysplastic Barrett's esophagus and intramucosal adenocarcinoma.MicroRNA profile in neosquamous esophageal mucosa following ablation of Barrett's esophagus.

P2860

Q37741832-654DD6DC-C93C-4C73-A0F2-CEE7867C99B3 Q41426289-696D08E8-F7A0-447D-96B1-F69DB395C581

P2860

Molecular biomarkers and ablative therapies for Barrett's esophagus.

Item

http://www.wikidata.org/entity/Q38051702

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Molecular biomarkers and ablative therapies for Barrett's esophagus.

@en

type

Item

label

Molecular biomarkers and ablative therapies for Barrett's esophagus.

@en

prefLabel

Molecular biomarkers and ablative therapies for Barrett's esophagus.

@en

P1476

Molecular biomarkers and ablative therapies for Barrett's esophagus.

@en

P2093

Damian J Hussey

http://www.w3.org/2001/XMLSchema#string

David I Watson

http://www.w3.org/2001/XMLSchema#string

George C Mayne

http://www.w3.org/2001/XMLSchema#string

Jacob A Chisholm

http://www.w3.org/2001/XMLSchema#string

P2860

NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma

Durability of radiofrequency ablation in Barrett's esophagus with dysplasia

Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study

Eradication of Barrett's mucosa with argon plasma coagulation and acid suppression: immediate and mid term results

CDK inhibitors: positive and negative regulators of G1-phase progression

The Ki-67 protein: from the known and the unknown

Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk

Radiofrequency ablation in Barrett's esophagus with dysplasia

CDX2 expression is progressively decreased in human gastric intestinal metaplasia, dysplasia and cancer

The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells

P304

567-581

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/EGH.12.39

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23061708

http://www.w3.org/2001/XMLSchema#string

P921

biomarker

Molecular biomarkers and ablative therapies for Barrett's esophagus.

about

P2860

P2860

Molecular biomarkers and ablative therapies for Barrett's esophagus.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921